Cargando…

Predicting AT(N) pathologies in Alzheimer’s disease from blood-based proteomic data using neural networks

BACKGROUND AND OBJECTIVE: Blood-based biomarkers represent a promising approach to help identify early Alzheimer’s disease (AD). Previous research has applied traditional machine learning (ML) to analyze plasma omics data and search for potential biomarkers, but the most modern ML methods based on d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yuting, Ghose, Upamanyu, Buckley, Noel J., Engelborghs, Sebastiaan, Sleegers, Kristel, Frisoni, Giovanni B., Wallin, Anders, Lleó, Alberto, Popp, Julius, Martinez-Lage, Pablo, Legido-Quigley, Cristina, Barkhof, Frederik, Zetterberg, Henrik, Visser, Pieter Jelle, Bertram, Lars, Lovestone, Simon, Nevado-Holgado, Alejo J., Shi, Liu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Aging Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746615/ https://www.ncbi.nlm.nih.gov/pubmed/36523958 http://dx.doi.org/10.3389/fnagi.2022.1040001

Ejemplares similares

Plasma Proteomic Biomarkers Relating to Alzheimer’s Disease: A Meta-Analysis Based on Our Own Studies
por: Shi, Liu, et al.
Publicado: (2021)

The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics
por: Bos, Isabelle, et al.
Publicado: (2018)

Genome-Wide Association Study of Alzheimer’s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery Dataset
por: Homann, Jan, et al.
Publicado: (2022)

Inflammatory biomarkers in Alzheimer's disease plasma
por: Morgan, Angharad R., et al.
Publicado: (2019)

A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort
por: Stamate, Daniel, et al.
Publicado: (2019)

Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer’s Disease Multimodal Biomarker Discovery Cohort
por: Westwood, Sarah, et al.
Publicado: (2020)

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
por: Shi, Liu, et al.
Publicado: (2019)

Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation
por: Neumann, Alexander, et al.
Publicado: (2022)

Determining the Molecular Pathways Underlying the Protective Effect of Non-Steroidal Anti-Inflammatory Drugs for Alzheimer's Disease: A Bioinformatics Approach
por: Nevado-Holgado, Alejo J, et al.
Publicado: (2016)

Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer’s Disease biomarker discovery cohort
por: Kim, Min, et al.
Publicado: (2019)

Sex-Specific Metabolic Pathways Were Associated with Alzheimer’s Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort
por: Xu, Jin, et al.
Publicado: (2021)

Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning
por: Neumann, Alexander, et al.
Publicado: (2023)

Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset
por: Hong, Shengjun, et al.
Publicado: (2020)

The relationship between isolated hypertension with brain volumes in UK Biobank
por: Newby, Danielle, et al.
Publicado: (2022)

CSF Proteomic Alzheimer’s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals
por: Tijms, Betty Marije, et al.
Publicado: (2021)

MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study
por: ten Kate, Mara, et al.
Publicado: (2018)

Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimer’s disease
por: Winchester, Laura M., et al.
Publicado: (2018)

Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics
por: Tijms, Betty M, et al.
Publicado: (2020)

Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer’s Disease Pathology
por: Shi, Liu, et al.
Publicado: (2020)

Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank
por: Nevado-Holgado, Alejo J, et al.
Publicado: (2016)

The intracerebral injection of Aβ(1-42) oligomers does not invariably alter seizure susceptibility in mice
por: Vande Vyver, Maxime, et al.
Publicado: (2023)

Comparative effect of metformin versus sulfonylureas with dementia and Parkinson’s disease risk in US patients over 50 with type 2 diabetes mellitus
por: Newby, Danielle, et al.
Publicado: (2022)

ANMerge: A Comprehensive and Accessible Alzheimer’s Disease Patient-Level Dataset
por: Birkenbihl, Colin, et al.
Publicado: (2021)

Survival-Span Method: How to Qualitatively Estimate Lifespan to Improve the Study of Aging, and not Disease, in Aging Studies
por: Adelöf, Julia, et al.
Publicado: (2021)

Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer’s Disease
por: Kim, Min, et al.
Publicado: (2017)

APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease
por: Konijnenberg, Elles, et al.
Publicado: (2020)

Trends across 20 years in multiple indicators of functioning among older adults in the Netherlands
por: Timmermans, Erik J, et al.
Publicado: (2019)

Genetic and Real-World Clinical Data, Combined with Empirical Validation, Nominate Jak-Stat Signaling as a Target for Alzheimer’s Disease Therapeutic Development
por: Nevado-Holgado, Alejo J., et al.
Publicado: (2019)

Cross-sectional and longitudinal analyses of outdoor air pollution exposure and cognitive function in UK Biobank
por: Cullen, Breda, et al.
Publicado: (2018)

The promise of multi-omics approaches to discover biological alterations with clinical relevance in Alzheimer’s disease
por: Clark, Christopher, et al.
Publicado: (2022)

Diffusion Kurtosis Imaging: A Possible MRI Biomarker for AD Diagnosis?
por: Struyfs, Hanne, et al.
Publicado: (2015)

Unreliable Evidence: 2 Sources of Uncertainty During Perceptual Choice
por: Michael, Elizabeth, et al.
Publicado: (2015)

Comorbidity between Alzheimer’s disease and major depression: a behavioural and transcriptomic characterization study in mice
por: Martín-Sánchez, Ana, et al.
Publicado: (2021)

CSF biomarker analysis of ABCA7 mutation carriers suggests altered APP processing and reduced inflammatory response
por: Duchateau, Lena, et al.
Publicado: (2023)

Effective connectivity of the subthalamic nucleus–globus pallidus network during Parkinsonian oscillations
por: Nevado-Holgado, Alejo J, et al.
Publicado: (2014)

NRF2 deficiency replicates transcriptomic changes in Alzheimer's patients and worsens APP and TAU pathology
por: Rojo, Ana I., et al.
Publicado: (2017)

Harmonization of brain PET images in multi-center PET studies using Hoffman phantom scan
por: Shekari, Mahnaz, et al.
Publicado: (2023)

Reduced Inter-Voxel White Matter Integrity in Subjective Cognitive Decline: Diffusion Tensor Imaging With Tract-Based Spatial Statistics Analysis
por: Chao, Yi-Ping, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_85fhl3n7n29vhqoo09i4jlee6g